GlobeNewswire by notified

Vallourec finalizes the sale of Valinox Nucléaire SAS to Framatome

Share

Press release

Vallourec finalizes the sale of ValinoxNucléaire SAS to Framatome

Boulogne-Billancourt, June 1st, 2021 – Vallourec, world leader in premium tubular solutions, announces today that it has finalized the sale to Framatome of the company Valinox Nucléaire SAS, located at the French production facility in Montbard (Burgundy, Côte d’Or). Founded in 1974, Valinox Nucléaire SAS – France is specialized in the manufacturing of tubes for nuclear islands.

All required regulatory approvals and authorizations have been obtained and employee representative bodies have been consulted, making this transaction possible.

Edouard Guinotte, Chairman of the Vallourec Management Board, stated “the integration of Valinox into Framatome will offer it and its teams the best possible outlook. I have witnessed the high quality, skills and commitment of Valinox employees, and I wish them every success.

The acquisition of Valinox Nucléaire SAS by Framatome will allow it to fully integrate the French nuclear sector, to benefit from potential synergies with this major player and to provide it with new sales opportunities.

About Vallourec

Vallourec is a world leader in premium tubular solutions for the energy markets and for challenging industrial applications such as oil and gas wells in harsh environments, new generation power plants, daring architectural projects, and high-performance mechanical equipment. Vallourec's pioneering spirit and cutting-edge R&D continually open new technological frontiers. Operating in more than 20 countries, its nearly 17,000 dedicated and passionate employees work hand-in-hand with their customers to offer much more than just tubes: they deliver innovative, reliable, competitive solutions to make every project possible.

Listed on the Euronext in Paris (ISIN code: FR0013506730, Ticker VK), Vallourec is included in the SBF 120 index and is eligible for the Deferred Settlement Service (SRD) Long-Only.

In the United States, Vallourec has a sponsored Level 1 American Depositary Receipt (ADR) program (ISIN code: US92023R4074, ticker: VLOWY). Parity between ADR and a Vallourec ordinary share has been set at 5:1.

For more information, please contact:

Investor relations
Jérôme Friboulet
Tel.: +33 (0)1 49 09 39 77
investor.relations@vallourec.com
Press relations
Héloïse Rothenbühler
Tel.: +33 (0)6 45 45 19 67
heloise.rothenbuhler@vallourec.com


Individual shareholder relations
Toll-Free Number: 0805 65 10 10
actionnaires@vallourec.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Golar LNG Limited - Announcement of filing of Form 20-F Annual Report28.3.2024 22:47:27 CET | Press release

Golar LNG Limited announces that it has filed its Form 20-F for the year ended December 31, 2023 with the Securities and Exchange Commission in the U.S. Form 20-F can be downloaded from the link below, is available on our website (www.golarlng.com) and shareholders may receive a hard copy free of charge upon request. March 28, 2024 The Board of Directors Hamilton, Bermuda Enquiries: Golar Management Limited: + 44 207 063 7900 Stuart Buchanan This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment GLNG 2023 Annual Report Form 20-F

Magna Posts 2023 Annual Report28.3.2024 22:26:07 CET | Press release

AURORA, Ontario, March 28, 2024 (GLOBE NEWSWIRE) -- Magna International Inc. (TSX: MG; NYSE: MGA) today announced that its 2023 Annual Report, including Management’s Discussion and Analysis and Audited Consolidated Financial Statements, Annual Information Form (AIF) and Form 40-F, are now available on the company’s website, www.magna.com. Magna has also filed these documents with the Canadian Securities Administrators (accessible through its website at www.sedarplus.ca) and the U.S. Securities and Exchange Commission (accessible through its website at www.sec.gov/edgar). Our 2024 Annual Meeting of Shareholders will be held on Thursday, May 9, 2024, commencing at 10:00 a.m. (Eastern Daylight Time). The meeting is being conducted as a virtual-only meeting accessible at www.virtualshareholdermeeting.com/MGA2024. Magna will provide a paper copy of its audited financial statements as contained in our 2023 Annual Report to Shareholders, free of charge, on request through our website, www.mag

Fortuna files Form 40-F, Annual Report28.3.2024 22:00:00 CET | Press release

VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE: FSM) (TSX: FVI) reports that the Company has filed today its fiscal 2023 annual report on Form 40-F with the U.S. Securities and Exchange Commission (“SEC”). The Form 40-F, which includes the Company’s fiscal 2023 annual audited financial statements, management’s discussion and analysis, and annual information form, is available on the Company’s website and on the SEC´s website. Printed copies of the annual financial statements are available free of charge to Fortuna shareholders upon written request. About Fortuna Silver Mines Inc. Fortuna Silver Mines Inc. is a Canadian precious metals mining company with five operating mines in Argentina, Burkina Faso, Côte d'Ivoire, Mexico, and Peru. Sustainability is integral to all our operations and relationships. We produce gold and silver and generate shared value over the long-term for our stakeholders through efficient production, environmental p

Nokia Corporation: Repurchase of own shares on 28.03.202428.3.2024 21:30:00 CET | Press release

Nokia Corporation Stock Exchange Release 28 March 2024 at 22:30 EET Nokia Corporation: Repurchase of own shares on 28.03.2024 Espoo, Finland – On 28 March 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL467,1243.29CEUX--BATE--AQEU--TQEX--Total467,1243.29 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 202328.3.2024 21:28:47 CET | Press release

Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 advancing toward interim analysis planned in 2024Orexin Agonist Program: Clinical proof-of-concept data for ORX750 in sleep-deprived healthy volunteers planned in 2024 LockBody® Technology Platform: Ongoing Phase 1/2a study of LB101 (PD-L1xCD47)for the treatment of solid tumors BOSTON and LONDON, March 28, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported recent business highlights and financial results for the fourth quarter and full-year ended December 31, 2023. “This is an exciting and pivotal time for Centessa,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa. “We are laser focused on executing the PRESent registrational studies for SerpinPC, a potential first-in-class subcutaneously administered therapy with a differentiated safety profile for individuals with he

HiddenA line styled icon from Orion Icon Library.Eye